EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Cross‐Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real‐World Evidence

Maria Melinder iD, Fabian Windfuhr iD, Tanja Dahlqvist, Carla Torre iD, Bruno Sepodes iD, Peter G M Mol iD, Diogo Almeida iD, Isabella Ekheden iD, Nils Feltelius iD, Kit Roes iD, Sieta T de Vries iD, Björn Wettermark iD

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Maria Melinder und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Evidence-Based Medicine. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess views among different stakeholders around evidence needs during assessment of clinical effects across the medicinal product life cycle, with a focus on real‐world evidence (RWE) in regulatory and health technology assessor (HTA)/payer decision‐making.

Methods

A cross‐sectional survey was distributed between November 2023–January 2024 to 1210 European regulators, HTAs, payers, and other stakeholders (i.e., industry, academia, healthcare professionals, and patient representatives). The survey included questions on their experience and views on evidence needs, which were analysed descriptively and with non‐parametric testing.

Results

191 respondents (110 regulators, 24 HTA/payers and 57 others) from 32 European countries completed the survey (response rate: 16%). Most respondents were between 41–60 years and 53% had > 10 years of work experience. Respondents were least confident in assessing evidence based on adjusted indirect comparisons and network meta‐analyses. Randomization and clinically relevant endpoints were considered most relevant in studies, while country‐specific data and patient preferences were considered least important. Respondents acknowledged that there are uncertainties on the clinical effect of medicinal products in the different stages of the medicinal product life cycle, but the views on the usefulness of RWE to address these uncertainties varied across stakeholder groups and life‐cycle stages. RWE was considered most likely to be accepted as supplementary evidence for orphan diseases and when randomized controlled trials (RCTs) are infeasible.

Conclusion

Our findings highlight opportunities and challenges in using RWE to reduce uncertainties in decision‐making around medicinal products. This may contribute to a dialogue on how and when to augment evidence from RCTs with RWE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalEvidence-Based MedicineCross-Sectional StudiesEuropeHumansSurveys and QuestionnairesDecision MakingAdultMiddle AgedStakeholder Participation

Stichwörter der Autor:innen

RWEevidence needshealth technology assessmentreal world evidenceregulatory decision‐makingregulatory science

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
  • Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines of the University of Lisbon (iMED.ULisboa), Lisboa, Portugal.
  • Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
  • Department of Clinical Pharmacology, Karolinska Institutet, Solna, Sweden.

ORCID-Profile: Maria Melinder, Fabian Windfuhr, Carla Torre, Bruno Sepodes, Peter G M Mol, Diogo Almeida, Isabella Ekheden, Nils Feltelius, Kit Roes, Sieta T de Vries, Björn Wettermark

Förderung

  • HORIZON EUROPE Health

Zitieren

APA

Melinder, M., Windfuhr, F., Dahlqvist, T., Torre, C., Sepodes, B., Mol, P. G. M., Almeida, D., Ekheden, I., Feltelius, N., Roes, K., de Vries, S. T., & Wettermark, B. (2026). A Cross‐Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real‐World Evidence. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70358

Vancouver

Melinder M, Windfuhr F, Dahlqvist T, Torre C, Sepodes B, Mol PGM, et al. A Cross‐Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real‐World Evidence. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70358

BibTeX
@article{Melinder2026,
  author = {Melinder, Maria and Windfuhr, Fabian and Dahlqvist, Tanja and Torre, Carla and Sepodes, Bruno and Mol, Peter G M and Almeida, Diogo and Ekheden, Isabella and Feltelius, Nils and Roes, Kit and de Vries, Sieta T and Wettermark, Björn},
  title = {A Cross‐Sectional Survey of Evidence Needs for Medicinal Products in Europe With a Focus on Real‐World Evidence},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70358}
}
Kostenlos starten →